A new non-pharmacological vacuum therapy for female sexual dysfunction

Kevin L. Billups, Laura Berman, Jennifer Berman, Michael E. Metz, Margaret E. Glennon, Irwin Goldstein

Research output: Contribution to journalArticlepeer-review

91 Scopus citations


Although Female Sexual Dysfunction (FSD) affects 40% of American women, there is no FDA-approved pharmaceutical therapy. The ER OS-CTD™ (Clitoral Therapy Device, UroMetrics, Inc., St. Paul, MN) treatment is the first FDA cleared-to-market therapy for FSD. Clitoral engorgement is believed to play an important role in female sexual arousal and overall sexual satisfaction. The EROS-CTD is a small, battery-powered device designed to enhance clitoral engorgement, increase blood flow to the clitoris, and ultimately improve arousal in women with FSD. The objective of this study was to assess the effectiveness of the EROS-CTD on sexual arousal (genital sensation, vaginal lubrication, ability to reach orgasm, and sexual satisfaction) in normal volunteers and women with FSD.

Original languageEnglish (US)
Pages (from-to)435-441
Number of pages7
JournalJournal of Sex and Marital Therapy
Issue number5
StatePublished - Oct 2001

ASJC Scopus subject areas

  • Clinical Psychology


Dive into the research topics of 'A new non-pharmacological vacuum therapy for female sexual dysfunction'. Together they form a unique fingerprint.

Cite this